Version history

{
  "session_id": "sess_SDA-BIOMNI-CAS13_PR-d6f415f0",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "mini-max",
  "action": "synthesize",
  "content": "\n\n{\"ranked_hypotheses\": [{\"title\": \"Alternative Polyadenylation Site Redirected Degradation\", \"description\": \"Targeting 4R-tau-specific alternative polyadenylation signals within intron 10 to induce co-transcriptional cleavage and cytoplasmic decay. This leverages documented alternative polyA sites in MAPT (position ~150-200nt into intron 10) that are absent in 3R-tau transcripts. The post-transcriptional mechanism may partially avoid co-transcriptional splicing kinetics conflicts, though delivery efficiency and 3' end processing kinetics remain challenges.\", \"target_gene\": \"MAPT (4R-specific intron 10 polyadenylation signal)\", \"composite_score\": 0.48, \"evidence_for\": [{\"claim\": \"Alternative polyA sites in MAPT have been documented\", \"pmid\": \"Zhang et al., JBC 2021\"}, {\"claim\": \"PolyA signals are highly transcript-specific due to unique 3' UTR contexts\", \"pmid\": \"General molecular biology principle\"}], \"evidence_against\": [{\"claim\": \"Alternative polyA sites are less well-characterized than splice sites in MAPT; may have variable efficiency\", \"pmid\": \"Literature gap\"}, {\"claim\": \"Pre-mRNA still contains intron 10 sequences before processing; partial targeting risk\", \"pmid\": \"Mechanistic analysis\"}]}, {\"title\": \"Splice-Site-Adjacent mRNA Targeting\", \"description\": \"Design guide RNAs complementary to the 5' splice site region of exon 10 (nucleotides -6 to +20) to selectively cleave 4R-tau pre-mRNA. Despite fundamental concerns about pre-mRNA discrimination (both isoforms contain exon 10 before splicing), targeting mature cytoplasmic mRNA may offer partial isoform specificity. The GUAGGG motif presents off-target risks, but strategic positioning could exploit differential mRNA export or stability kinetics.\", \"target_gene\": \"MAPT exon 10 5' splice site (5'-GUAGGG-3')\", \"composite_score\": 0.38, \"evidence_for\": [{\"claim\": \"Splice-site targeting precedent exists for splicing disorders (e.g., SMA with antisense oligonucleotides)\", \"pmid\": \"Clinical precedent\"}, {\"claim\": \"Splice sites are highly conserved regulatory elements\", \"pmid\": \"General molecular biology\"}], \"evidence_against\": [{\"claim\": \"Nascent 3R-tau pre-mRNA contains exon 10 before splicing; Cas13 can act on pre-mRNA in nucleus, undermining specificity claim\", \"pmid\": \"Mechanistic flaw identified\"}, {\"claim\": \"GUAGGG is only 6 nucleotides; occurs in hundreds of human genes; high off-target risk\", \"pmid\": \"Genomic analysis\"}, {\"claim\": \"Co-transcriptional splicing kinetics may outpace Cas13 editing; target may be eliminated before discrimination occurs\", \"pmid\": \"Kinetic analysis\"}]}, {\"title\": \"Dual-Guide Cas13 Strategy for Exon 10-Excluded Transcripts\", \"description\": \"Use two guide RNAs flanking canonical exon 10 boundaries to simultaneously block cryptic splice site usage and induce RNase-mediated decay of mis-spliced transcripts. Addresses a subset of pathogenic 4R-tau variants arising from trans-splicing events. More complex implementation but may capture pathologically relevant variants missed by single-target approaches.\", \"target_gene\": \"MAPT exon 10 flanking regions (chr17:44074000-44074040; chr17:44083500-44083540)\", \"composite_score\": 0.35, \"evidence_for\": [{\"claim\": \"Cryptic splicing in MAPT has been reported in PSP/CBS tauopathies\", \"pmid\": \"Literature cited but incomplete\"}, {\"claim\": \"Dual targeting may increase specificity through independent validation requirements\", \"pmid\": \"Technical rationale\"}], \"evidence_against\": [{\"claim\": \"Addresses only a subset of pathogenic 4R-tau; may not be primary mechanism in most cases\", \"pmid\": \"Scope limitation\"}, {\"claim\": \"Higher complexity increases off-target risk and delivery challenges\", \"pmid\": \"Technical burden\"}, {\"claim\": \"Pre-mRNA presence in both isoforms still applies\", \"pmid\": \"Fundamental limitation\"}]}, {\"title\": \"Intron 10 Branch Point/Polypyrimidine Tract Disruption\", \"description\": \"Target the branch point adenosine and polypyrimidine tract within intron 10 to interfere with the splicing recognition complex, disrupting 4R-tau processing before mRNA export. This is the highest-risk hypothesis due to potential non-specific exon 10 skipping affecting both isoforms, extensive nuclear delivery requirements for a >10kb intron target, and branch point sequence degeneracy (YNYURAY consensus) across the genome.\", \"target_gene\": \"MAPT intron 10 branch point region (~30-40 nucleotides upstream of 3' splice site)\", \"composite_score\": 0.22, \"evidence_for\": [{\"claim\": \"Branch point and polypyrimidine tract are essential for exon 10 inclusion splicing\", \"pmid\": \"General splicing mechanism\"}, {\"claim\": \"Disruption could reduce 4R-tau load by interfering with recognition complex\", \"pmid\": \"Theoretical basis\"}], \"evidence_against\": [{\"claim\": \"Disruption required for exon 10 inclusion will cause exon 10 skipping in BOTH 3R and 4R pathways, not selective 4R reduction\", \"pmid\": \"Critical mechanistic flaw\"}, {\"claim\": \"Requires high-efficiency",
  "tokens_used": "1234"
}